

PROVENTIL®

brand of albuterol sulfate

Inhalation Solution, 0.083%*

*Potency expressed as albuterol


PRODUCT
INFORMATION

FOR ORAL INHALATION ONLY

Rx only

DESCRIPTION:

PROVENTIL Inhalation Solution contains albuterol sulfate, USP, the racemic form of albuterol, a relatively selective beta₂-adrenergic bronchodilator. Albuterol sulfate has the chemical name α '-(*tert*-Butylamino) methyl]-4-hydroxy-*m*-xylene- α , α -diol sulfate (2:1) (salt), and the following structural formula:



Albuterol sulfate is a white crystalline powder, soluble in water and slightly soluble in ethanol.

The World Health Organization's recommended name for albuterol base is salbutamol.

PROVENTIL Inhalation Solution is a clear, colorless to light yellow solution and requires no dilution before administration by nebulization.

Each mL of PROVENTIL Inhalation Solution 0.083% contains 0.83 mg of albuterol (as 1.0 mg of albuterol sulfate) in an isotonic aqueous solution containing sodium chloride. Sulfuric Acid may be added to adjust pH (3 – 5). PROVENTIL Inhalation Solution contains no sulfiting agents or preservatives.

CLINICAL PHARMACOLOGY:

The primary action of beta-adrenergic drugs, including albuterol, is to stimulate adenyl cyclase, the enzyme which catalyzes the formation of cyclic-3', 5'-adenosine monophosphate (cyclic AMP) from adenosine triphosphate (ATP) in beta-adrenergic cells. The cyclic AMP thus formed mediates the cellular responses. Increased cyclic AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.

In vitro studies and *in vivo* pharmacologic studies have demonstrated that albuterol has a preferential effect on beta₂-adrenergic receptors compared with isoproterenol. While it is recognized that beta₂-adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta₂-receptors in the human heart existing in a concentration between 10% and 50%. The precise function of these receptors has not been established.

In controlled clinical trials, albuterol has been shown to have more effect on the respiratory tract, in the form of bronchial smooth muscle relaxation, than isoproterenol at comparable doses while producing fewer cardiovascular effects. Controlled clinical studies and other clinical experience have shown that inhaled albuterol, like other beta-adrenergic agonist drugs, can produce a significant cardiovascular effect in some patients, as measured by pulse rate, blood pressure, symptoms, and/or ECG changes.

Albuterol is longer acting than isoproterenol in most patients by any route of administration because it is not a substrate for the cellular uptake processes for catecholamines nor for catechol-*O*-methyl transferase. The effects of rising doses of albuterol and isoproterenol aerosols were studied in volunteers and asthmatic patients. Results in normal volunteers indicated that the propensity for increase in heart rate for albuterol is 1/2 to 1/4 that of isoproterenol. In asthmatic patients similar cardiovascular differentiation between the two drugs was also seen.

Preclinical: Intravenous studies in rats with albuterol sulfate have demonstrated that albuterol crosses the blood-brain barrier and reaches brain concentrations that are amounting to approximately 5.0% of the plasma concentrations. In structures outside the blood-brain barrier (pineal and pituitary glands), albuterol concentrations were found to be 100 times those in the whole brain.

Studies in laboratory animals (minipigs, rodents, and dogs) have demonstrated the occurrence of cardiac arrhythmias and sudden death (with histologic evidence of myocardial necrosis) when beta-agonists and methylxanthines are administered concurrently. The clinical significance of these findings is unknown.

Pharmacokinetics: After either IPPB or nebulizer administration in asthmatic patients, less than 20% of a single albuterol dose was absorbed; the remaining amount was recovered from the nebulizer and apparatus and expired air. Most of the absorbed dose was recovered in the urine 24 hours after drug administration. Following a 3.0 mg dose of nebulized albuterol, the maximum albuterol plasma level at 0.5 hour was 2.1 ng/mL (range 1.4 to 3.2 ng/mL). It has been demonstrated that following oral administration of 4 mg of albuterol, the elimination half-life was 5 to 6 hours.

Clinical Trials: In controlled clinical trials, most patients exhibited an onset of improvement in pulmonary function within 5 minutes as determined by FEV₁. FEV₁ measurements also showed that the maximum average improvement in pulmonary function usually occurred at approximately 1 hour following inhalation of 2.5 mg of albuterol by compressor-nebulizer, and remained close to peak for 2 hours. Clinically significant improvement in pulmonary function (defined as maintenance of a 15% or more increase in FEV₁ over baseline values) continued for 3 to 4 hours in most patients and in some patients continued up to 6 hours.

INDICATIONS AND USAGE:

PROVENTIL Inhalation Solution is indicated for the relief of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease and acute attacks of bronchospasm.

CONTRAINDICATIONS:

PROVENTIL Inhalation Solution is contraindicated in patients with a history of hypersensitivity to albuterol or any of its components.

WARNINGS:

Deterioration of Asthma: Asthma may deteriorate acutely over a period of hours, or chronically over several days or longer. If the patient needs more doses of PROVENTIL Inhalation Solution than usual, this may be a marker of destabilization of asthma and requires re-evaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids.

Use of Anti-inflammatory Agents: The use of beta-adrenergic agonist bronchodilators alone may not

be adequate to control asthma in many patients. Early consideration should be given to adding anti-inflammatory agents, e.g., corticosteroids.

Paradoxical Bronchospasm: PROVENTIL Inhalation Solution can produce paradoxical bronchospasm, which may be life-threatening. If paradoxical bronchospasm occurs, PROVENTIL Inhalation Solution should be discontinued immediately and alternative therapy instituted. It should be recognized that paradoxical bronchospasm, when associated with inhaled formulations, frequently occurs with the first use of a new vial.

Cardiovascular Effects: PROVENTIL Inhalation Solution, like all other beta-adrenergic agonists, can produce a clinically significant cardiovascular effect in some patients as measured by pulse rate, blood pressure, and/or symptoms. Although such effects are uncommon after administration of PROVENTIL Inhalation Solution at recommended doses, if they occur, the drug may need to be discontinued. In addition, beta-agonists have been reported to produce electrocardiogram (ECG) changes, such as flattening of the T wave, prolongation of the QT_c interval, and ST segment depression. The clinical significance of these findings is unknown. Therefore, PROVENTIL Inhalation Solution, like all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.

Immediate Hypersensitivity Reactions: Immediate hypersensitivity reactions may occur after administration of albuterol, as demonstrated by rare cases of urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema.

Microbial Contamination: To avoid microbial contamination, the entire contents of the unit-dose vial should be administered immediately after the vial has been opened for the first time.

PRECAUTIONS:

General: Albuterol, as with all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension; in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus; and in patients who are unusually responsive to sympathomimetic amines. Clinically significant changes in systolic and diastolic blood pressure have been seen and could be expected to occur in some patients after use of any beta-adrenergic bronchodilator.

Large doses of intravenous albuterol have been reported to aggravate pre-existing diabetes and ketoacidosis. As with other beta-agonist medications, albuterol may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects. The decrease is usually transient, not requiring potassium supplementation.

Information for Patients: See illustrated Patient's Instructions for Use.

General: The action of PROVENTIL Inhalation Solution may last up to 6 hours or longer. PROVENTIL Inhalation Solution should not be used more frequently than recommended. Do not increase the dose or frequency of doses of PROVENTIL Inhalation Solution without consulting your physician. If you find that treatment with PROVENTIL Inhalation Solution becomes less effective for symptomatic relief, your symptoms become worse, and/or you need to use the product more frequently than usual, you should seek medical attention immediately. While you are using PROVENTIL Inhalation Solution, other inhaled drugs and asthma medications should be taken only as directed by your physician. Common adverse effects include palpitations, chest pain, rapid heart rate, tremor, or nervousness. If you are pregnant or nursing, contact your physician about the use of PROVENTIL Inhalation Solution. Effective use of PROVENTIL Inhalation Solution includes an understanding of the way that it should be administered. See illustrated Patient's Instructions for Use.

Microbial Contamination: To avoid microbial contamination, the entire contents of the unit-dose vial should be administered immediately after the vial has been opened for the first time.

Mixing Different Inhalation Solutions: Drug compatibility (physical and chemical), efficacy, and safety of PROVENTIL Inhalation Solution when mixed with other drugs in a nebulizer have not been established.

Drug Interactions: Other short-acting sympathomimetic aerosol bronchodilators or epinephrine should not be used concomitantly with albuterol.

Beta Blockers: Beta-adrenergic receptor blocking agents not only block the pulmonary effect of beta-agonists, such as PROVENTIL Inhalation Solution, but may produce severe bronchospasm in asthmatic patients. Therefore, patients with asthma should not normally be treated with beta blockers. However, under certain circumstances, e.g., as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-adrenergic blocking agents in patients with asthma. In this setting, cardioselective beta blockers could be considered, although they should be administered with caution.

Diuretics: The ECG changes and/or hypokalemia that may result from the administration of nonpotassium-sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended use of the beta-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the coadministration of beta-agonists with nonpotassium-sparing diuretics.

Digoxin: Mean decreases of 16% to 22% in serum digoxin levels were demonstrated after single dose intravenous and oral administration of albuterol, respectively, to normal volunteers who had received digoxin for 10 days. The clinical significance of this finding for patients with obstructive airway disease who are receiving albuterol and digoxin on a chronic basis is unclear. Nevertheless, it would be prudent to carefully evaluate the serum digoxin levels in patients who are currently receiving digoxin and albuterol.

Monoamine Oxidase Inhibitors or Tricyclic Antidepressants: Albuterol should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, because the action of albuterol on the vascular system may be potentiated.

Carcinogenesis, Mutagenesis, and Impairment of Fertility: In a 2-year study in Sprague-Dawley rats, albuterol sulfate caused a significant dose-related increase in the incidence of benign leiomyomas of the mesovarium at and above dietary doses of 2 mg/kg (approximately 2 times the maximum recommended daily inhalation dose for adults on an mg/m² basis). In another study, this effect was blocked by the co-administration of propranolol, a nonselective beta-adrenergic antagonist.

In an 18-month study in CD-1 mice, albuterol sulfate showed no evidence of tumorigenicity at dietary doses up to 500 mg/kg (approximately 200 times the maximum recommended daily inhalation dose for adults on an mg/m² basis). In a 22-month study in the Golden Hamster, albuterol sulfate showed no evidence of tumorigenicity at dietary doses up to 50 mg/kg (approximately 25 times the maximum recommended daily inhalation dose for adults on an mg/m² basis).

Albuterol sulfate was not mutagenic in the Ames test with or without metabolic activation using tester strains *S. typhimurium* TA1537, TA1538, and TA98 or *E. coli* WP2, WP2uvrA, and WP67. No forward mutation was seen in yeast strain *S. cerevisiae* S9 nor any mitotic gene conversion in yeast strain *S. cerevisiae* JD1 with or without metabolic activation. Fluctuation assays in *S. typhimurium* TA98 and *E. coli* WP2, both with metabolic activation, were negative. Albuterol sulfate was not clastogenic in a human peripheral lymphocyte assay or in an AH1 strain mouse micronucleus assay.

Reproduction studies in rats demonstrated no evidence of impaired fertility at oral doses of albuterol sulfate up to 50 mg/kg (approximately 40 times the maximum recommended daily inhalation dose for adults on an mg/m² basis).

Teratogenic Effects – Pregnancy Category C: Albuterol sulfate has been shown to be teratogenic in mice. A study in CD-1 mice at subcutaneous (sc) doses at and above 0.25 mg/kg (corresponding to less than the maximum recommended daily inhalation dose for adults on a mg/m² basis), induced cleft palate formation in 5 of 111 (4.5%) fetuses. At an sc dose of 2.5 mg/kg (approximately equal to the maximum recommended daily inhalation dose for adults on an mg/m² basis) albuterol sulfate induced cleft palate formation in 10 of 108 (9.3%) fetuses. The drug did not induce cleft palate formation when administered at an sc dose of 0.025 mg/kg (corresponding to less than the maximum recommended daily inhalation dose for adults on an mg/m² basis). Cleft palate also occurred in 22 of 72 (30.5%) fetuses from females treated with 2.5 mg/kg isoproterenol (positive control) administered subcutaneously.

A reproduction study in Stride Dutch rabbits revealed cranioschisis in 7 of 19 (37%) fetuses when albuterol was administered orally at a dose of 50 mg/kg (approximately 80 times the maximum recommended daily inhalation dose for adults on an mg/m² basis).

Studies in pregnant rats with tritiated albuterol demonstrated that approximately 10% of the circulating maternal drug is transferred to the fetus. Disposition in the fetal lungs is comparable to maternal lungs, but fetal liver disposition is 1% of the maternal liver levels.

There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, albuterol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

During worldwide marketing experience, various congenital anomalies, including cleft palate and limb defects have been reported in the offspring of patients being treated with albuterol. Some of the mothers were taking multiple medications during their pregnancies. Because no consistent pattern of defects can be discerned, a relationship between albuterol use and congenital anomalies has not been established.

Use In Labor and Delivery – Use In Labor: Because of the potential for beta-agonist interference with uterine contractility, use of PROVENTIL® Inhalation Solution for relief of bronchospasm during labor should be restricted to those patients in whom the benefits clearly outweigh the risk.

Tocolysis: Albuterol has not been approved for the management of preterm labor. The benefit:risk ratio when albuterol is administered for tocolysis has not been established. Serious adverse reactions, including maternal pulmonary edema, have been reported during or following treatment of premature labor with beta-agonists, including albuterol.

Nursing Mothers: It is not known whether this drug is excreted in human milk. Because of the potential for tumorigenicity shown for albuterol in some animal studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use: Safety and effectiveness of PROVENTIL Inhalation Solution and solution for inhalation in children below the age of 12 years have not been established.

ADVERSE REACTIONS:

The results of clinical trials with PROVENTIL Inhalation Solution in 135 patients showed the following side effects which were considered probably or possibly drug related:

Percent Incidence of Adverse Reactions			
Reaction	Percent Incidence	Reaction	Percent Incidence
Central Nervous System		Cardiovascular	
Tremors	20	Tachycardia	1
Dizziness	7	Hypertension	1
Nervousness	4	Respiratory	
Headache	3	Bronchospasm	8
Insomnia	1	Cough	4
Gastrointestinal		Bronchitis	4
Nausea	4	Wheezing	1
Dyspepsia	1	Ear, nose and throat	
Ear, nose and throat		Nasal congestion	1
		Pharyngitis	<1

No clinically relevant laboratory abnormalities related to PROVENTIL Inhalation Solution were determined in these studies.

Cases of urticaria, angioedema, rash, bronchospasm, hoarseness, oropharyngeal edema, and arrhythmias (including atrial fibrillation, supraventricular tachycardia, and extrasystoles) have also been reported after the use of inhaled albuterol.

OVERDOSAGE: The expected symptoms with overdosage are those of excessive beta-adrenergic stimulation and/or occurrence or exaggeration of any of the symptoms listed under **ADVERSE REACTIONS**, e.g., angina, hypertension, tachycardia with rates up to 200 beats per minute, arrhythmias, nervousness, headache, tremor, dry mouth, palpitation, nausea, dizziness, malaise, and insomnia. In addition, seizures, hypotension, fatigue, and hypokalemia may also occur. As with all sympathomimetic aerosol medications, cardiac arrest and even death may be associated with abuse of PROVENTIL Inhalation Solution. Treatment consists of discontinuation of PROVENTIL Inhalation Solution together with appropriate symptomatic therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. There is insufficient evidence to determine if dialysis is beneficial for overdosage of PROVENTIL Inhalation Solution.

The oral median lethal dose of albuterol sulfate in mice is greater than 2000 mg/kg (approximately 810 times the maximum recommended daily inhalation dose for adults on an mg/m² basis). In mature rats, the subcutaneous (sc) median lethal dose of albuterol sulfate is approximately 450 mg/kg (approximately 360 times the maximum recommended daily inhalation dose for adults on an mg/m² basis). In small young rats, the sc median lethal dose is approximately 2000 mg/kg (approximately 1600 times the maximum recommended daily inhalation dose for adults on an mg/m² basis). The inhalation median lethal dose has not been determined in animals.

DOSAGE AND ADMINISTRATION:

The usual dosage for adults and pediatric patients 12 years of age and older is 2.5 mg of albuterol administered 3 to 4 times daily by nebulization. More frequent administration or higher doses are not recommended. To administer 2.5 mg of albuterol, administer the entire contents of one unit-dose vial (3 mL of 0.083% nebulizer solution) by nebulization. The flow rate is regulated to suit the particular nebulizer so that the PROVENTIL Inhalation Solution will be delivered over approximately 5 to 15 minutes.

Drug compatibility (physical and chemical), efficacy, and safety of PROVENTIL Inhalation Solution when mixed with other drugs in a nebulizer have not been established.

The use of PROVENTIL Inhalation Solution can be continued as medically indicated to control recurring bouts of bronchospasm. During treatment, most patients gain optimum benefit from regular use of the nebulizer solution.

If a previously effective dosage regimen fails to provide the usual relief, medical advice should be sought immediately, as this is often a sign of seriously worsening asthma which would require reassessment of therapy.

Microbial Contamination: To avoid microbial contamination, the entire contents of the unit-dose vial should be administered immediately after the vial has been opened for the first time.

The nebulizer should be cleaned in accordance with the manufacturer's instructions. Failure to do so could lead to bacterial contamination of the nebulizer and possible infection.

HOW SUPPLIED:

PROVENTIL Inhalation Solution, 0.083% is supplied in sterile unit dose vials of 3 mL each and enclosed in cartons of: 24 vials – NDC 0085-1806-01 (2 Pouches)

Storage: Store between 2°-25°C (36°-77°F). Protect from light by storing unused product in foil pouch. PROVENTIL Inhalation Solution, 0.083% is a clear, colorless to light yellow solution.

KEEP OUT OF REACH OF CHILDREN.

Manufactured by **Cardinal Health**
Woodstock, IL 60098 USA

Manufactured for **Schering Corporation**
Kenilworth, NJ 07033 USA

Copyright © 1986, 1999, Schering Corporation, Kenilworth, NJ 07033 USA. All rights reserved.
26004411 Rev. 6/04

PATIENT'S INSTRUCTIONS FOR USE

PROVENTIL®
brand of albuterol sulfate
Inhalation Solution, 0.083%*

*Potency expressed as albuterol

Note: This is a unit-dose vial. No dilution is required. Read complete instructions carefully before using.



Figure 1



Figure 2




Figure 3

1. Twist open the top of one vial and pour the entire contents into the nebulizer reservoir. (Figure 1).
2. Connect the nebulizer reservoir to the mouthpiece or face mask (Figure 2).
3. Connect the nebulizer to the compressor.
4. Sit in a comfortable, upright position; place the mouthpiece in your mouth (Figure 3) (or put on the face mask); and turn on the compressor.
5. Breathe as calmly, deeply, and evenly as possible until no more mist is formed in the nebulizer chamber (about 5 to 15 minutes). At this point, the treatment is finished.
6. Clean the nebulizer (see manufacturer's instructions). Failure to clean the nebulizer in accordance with the manufacturer's instructions could lead to bacterial contamination of the nebulizer and possible infection.

Note: Use only as directed by your doctor. More frequent administration or higher doses are not recommended.

Mixing Compatibility: The safety and effectiveness of PROVENTIL Inhalation Solution have not been determined when one or more drugs are mixed with it in a nebulizer. Check with your doctor before mixing any medications in your nebulizer.

Microbial Contamination: To avoid microbial contamination, the entire contents of the unit-dose vial should be administered immediately after the vial has been opened for the first time.

Storage: Store between 2°-25°C (36°-77°F). Protect from light by storing unused product in foil pouch. PROVENTIL Inhalation Solution, 0.083% is a clear, colorless to light yellow solution.

ADDITIONAL INSTRUCTIONS:

Manufactured by **Cardinal Health**
Woodstock, IL 60098 USA

Manufactured for **Schering Corporation**
Kenilworth, NJ 07033 USA

Copyright © 1986, 1999, Schering Corporation, Kenilworth, NJ 07033 USA. All rights reserved.
26004411 Rev. 6/04